Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib + Bicalutamide in HRPC
NCT00757692Phase 2Completed
- Sponsor
- BC Cancer
- Start
- Jan 2009
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vandetanib in prostate cancer (PCa) (2 arms), sponsored by BC Cancer. Primary endpoint: Prostate Specific Antigen Response. Started Jan 2009; status: completed.
02
Drugs
vandetanib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00757692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757692.